Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term dt [Drug Therapy]. Found 37 abstracts

no pagination
Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clinical Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leukemia Research. 2006 Jan;30(1):109-14.
Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 2005 May;15 Suppl 1:12-7.
Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology. 2005 Mar;6(2):115-20.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Held-Warmkessel J. Managing three critical cancer complications. Nursing. 2005 Jan;35(1):58-63; quiz 63-4.
Langer CJ. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer. Clinical lung cancer. 2005 Jan;6(5):314-6, 2005 Mar.
Rogers B. Looking at lymphoma and leukemia. Nursing. 2005 Jul;35(7):56-63; quiz 63-4.
Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clinical Colorectal Cancer. 2005 Jul;5(2):108-13.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Cancer Research. 2004 Dec;10(23):8048-58.
Horwitz EM, Feigenberg SJ, Uzzo RG. The treatment of non-metastatic prostate cancer with external beam radiation therapy. Minerva Urologica e Nefrologica. 2004 Jun;56(2):173-88.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
Feigenberg SJ, Wolk KL, Yang CH, Morris CG, Zlotecki RA. Celecoxib to decrease urinary retention associated with prostate brachytherapy. Brachytherapy. 2003 Jan;2(2):103-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term dt [Drug Therapy]

dt [Drug Therapy] tu [Therapeutic Use] Female Antineoplastic Agents 0 (Antineoplastic Agents) Male pa [Pathology] Middle Aged aa [Analogs & Derivatives] Antineoplastic Combined Chemotherapy Protocols me [Metabolism] pd [Pharmacology] ae [Adverse Effects] Lung Neoplasms 0 (Antineoplastic Combined Chemotherapy Protocols) ai [Antagonists & Inhibitors] Treatment Outcome ad [Administration & Dosage] rt [Radiotherapy] Human Use] Neoplasm Staging di [Diagnosis] tu [Therapeutic sc [Secondary] Ovarian Neoplasms et [Etiology] Adult mo [Mortality] Colorectal Neoplasms Survival Analysis Camptothecin Brain Neoplasms 80 and over Aged Deoxycytidine 7689-03-4 (Camptothecin) mt [Methods] tu [Therapeutic Use] co [Complications] 951-77-9 (Deoxycytidine) Prostatic Neoplasms Aged Bone Neoplasms Prognosis 0 (Piperazines) Radiotherapy Fluorouracil Monoclonal Antibodies Predictive Value of Tests Antineoplastic) 0 (Antimetabolites Patient Education Comparative Study Cisplatin Non-Small-Cell Lung Carcinoma Lymphoma 0 (Enzyme Inhibitors) Protein Kinase Inhibitors ch [Chemistry] de [Drug Effects] EC 2-7-1-37 (Protein Kinases) pc [Prevention & Control] Phenotype Sirolimus EC 2-7-1-112 (Protein-Tyrosine Kinase) Biological Tumor Markers Piperazines EC 2-7-1 (mTOR protein) 53123-88-9 (Sirolimus) Proportional Hazards Models 103882-84-4 (gemcitabine) Phosphorylation Enzyme Inhibitors Neoplasm Metastasis Pyrimidines Adjuvant Chemotherapy Non-US Gov't Support 100286-90-6 (irinotecan) Taxoids Adjuvant Radiotherapy 15663-27-1 (Cisplatin) 51-21-8 (Fluorouracil) Drug Dose-Response Relationship Protein-Tyrosine Kinase th [Therapy] Protein Kinases 152459-95-5 (imatinib) NIH Research Support-Extramural 0 (Protein Kinase Inhibitors) su [Surgery] 0 (Taxoids) Biological) 0 (Tumor Markers Antineoplastic Antimetabolites Local Neoplasm Recurrence Non-US Gov't Research Support Survival Rate ge [Genetics] Monoclonal) 0 (Antibodies 0 (Pyrimidines) 0 (Imidazoles) Dacarbazine 118072-93-8 (zoledronic acid) Liver Neoplasms Incidence 0 (cci 779) ai [Antagonists & Cell Adhesion US Gov't Research Support-PHS Biological Models Inappropriate ADH Syndrome Premenopause Secondary Hypertrophic Osteoarthropathy Reverse Transcriptase Polymerase Chain Reaction 0 (Diphosphonates) Imidazoles 0 (Morpholines) 0 (Neoplasm Proteins) Non-Steroidal Anti-Inflammatory Agents 184475-35-2 (gefitinib) Social Support Biological Availability Diphosphonates nu [Nursing] Feasibility Studies Radiotherapy Dosage EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) Rectal Neoplasms Epidermal Growth Factor Receptor Neoplastic Gene Expression Regulation 0 (rituximab) US Gov't Support-PHS Adenocarcinoma Cell Division Cell Survival ci [Chemically Induced] Sulfonamides Thymidine Phosphorylase Retrospective Studies Platelet-Derived Growth Factor) EC 2-7-1-112 (Receptors Kidney Neoplasms Drug Hypersensitivity Quinazolines Heterologous Transplantation Gastrointestinal Stromal Tumors EC 2-7-1-37 (proto-oncogene protein akt) Cultured Tumor Cells Phytogenic Antineoplastic Agents 0 (Interferon-alpha) North America Ribonucleotide Reductases
Last updated on Wednesday, August 12, 2020